Literature DB >> 11559866

Factors affecting smoking in schizophrenia.

S Beratis1, A Katrivanou, P Gourzis.   

Abstract

There is an increased frequency of smoking among patients with schizophrenia. However, it is unknown whether the smoking behavior of the patients is similar in all schizophrenia subtypes, as well as which is the relationship between smoking initiation and disease onset. Four hundred six patients with DSM-IV schizophrenia were interviewed to determine the smoking status in relationship to gender and schizophrenic subtype, and to other factors that could affect or be affected by smoking. The frequency of smoking among patients (58%) was significantly greater than in subjects from the general population (42%) (P =.000005). Male patients smoked significantly more frequently (70%) than the corresponding control subjects (50%) (P =.000006), whereas the difference failed to reach significance between female patients (41%) and control subjects (32%). Among male patients, the number of smokers was significantly greater than in the controls in the paranoid (77%), undifferentiated (72%), and residual (78%) subtypes, whereas there was no significant difference in the disorganized (44%) and catatonic (22%) subtypes. The findings show that the frequency of smoking in schizophrenia patients increases with increasing positive symptoms and decreases with increasing negative symptoms. Male and female smoking patients consumed approximately 10 cigarettes per day more than the corresponding control subjects (P <.000001). In 86% of the patients, smoking initiation occurred before the disease onset. Among patients who smoked, smoking initiation and disease onset occurred at age 18.7 +/- 4.4 and 24.1 +/- 6.1 years, respectively (P <.000001). It appears that smoking in schizophrenia is influenced by gender and subtype. However, the nature of this association remains uncertain because in the vast majority of the patients smoking initiation occurs earlier than the disease onset. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11559866     DOI: 10.1053/comp.2001.26273

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  26 in total

Review 1.  Antipsychotic-induced venous thromboembolism: a review of the evidence.

Authors:  Staffan Hägg; Olav Spigset
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients.

Authors:  Hsing-Kang Chen; Tsuo-Hung Lan; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06-23       Impact factor: 5.270

3.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

4.  Is initiation of smoking associated with the prodromal phase of schizophrenia?

Authors:  Kaisa Riala; Helinä Hakko; Matti Isohanni; Anneli Pouta; Pirkko Räsänen
Journal:  J Psychiatry Neurosci       Date:  2005-01       Impact factor: 6.186

5.  Correlates of secondhand tobacco smoke exposure among persons with severe and persistent mental illness (SPMI) accessing community mental health services.

Authors:  Chizimuzo T C Okoli; Joy L Johnson; Leslie Malchy
Journal:  Community Ment Health J       Date:  2009-02-03

Review 6.  Smoking in schizophrenic patients: A critique of the self-medication hypothesis.

Authors:  Francesca Manzella; Susan E Maloney; George T Taylor
Journal:  World J Psychiatry       Date:  2015-03-22

7.  Cognitive performance and smoking in first-episode psychosis: the self-medication hypothesis.

Authors:  Rafael Segarra; Arantzazu Zabala; Jose Ignacio Eguíluz; Natalia Ojeda; Edorta Elizagarate; Pedro Sánchez; Javier Ballesteros; Miguel Gutiérrez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-09-14       Impact factor: 5.270

8.  Nicotine consumption and schizotypy in first-degree relatives of individuals with schizophrenia and non-psychiatric controls.

Authors:  Michelle L Esterberg; Erin M Jones; Michael T Compton; Elaine F Walker
Journal:  Schizophr Res       Date:  2007-09-25       Impact factor: 4.939

9.  Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia.

Authors:  Alexandra I Zugno; Ricardo Filipe Julião; Josiane Budni; Ana Maria Volpato; Daiane B Fraga; Felipe D Pacheco; Pedro F Deroza; Renata D Luca; Mariana B de Oliveira; Alexandra S Heylmann; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-06-19       Impact factor: 3.584

10.  European network for promoting the physical health of residents in psychiatric and social care facilities (HELPS): background, aims and methods.

Authors:  Prisca Weiser; Thomas Becker; Carolin Losert; Köksal Alptekin; Loretta Berti; Lorenzo Burti; Alexandra Burton; Mojca Dernovsek; Eva Dragomirecka; Marion Freidl; Fabian Friedrich; Aneta Genova; Arunas Germanavicius; Ulaş Halis; John Henderson; Peter Hjorth; Taavi Lai; Jens Ivar Larsen; Katarzyna Lech; Ramona Lucas; Roxana Marginean; David McDaid; Maya Mladenova; Povl Munk-Jørgensen; Alexandru Paziuc; Petronela Paziuc; Stefan Priebe; Katarzyna Prot-Klinger; Johannes Wancata; Reinhold Kilian
Journal:  BMC Public Health       Date:  2009-08-28       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.